文献速递乳腺癌支持与姑息治疗

胚系BRCA1/2突变与乳腺癌新辅助化疗严重血液学毒性

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
PubMed 文献 · Eur J Cancer · 2021-01-07

该研究基于德国乳腺组(GBG)与妇科肿瘤工作组乳腺组(AGO-B)的早期三阴性乳腺癌(TNBC)研究数据,纳入1171例已知胚系BRCA1/2突变状态、接受蒽环-紫杉类新辅助化疗的患者,其中17.8%携带胚系BRCA1/2突变。第一周期中,胚系BRCA1/2突变组与野生型组中性粒细胞减少GIII-IV发生率分别为37.4%与35.7%(P=0.683),多因素回归显示胚系BRCA1/2突变并非中性粒细胞减少GIII-IV的预测因素(OR 1.26,95%CI 0.87-1.82,P=0.226)。结论认为胚系BRCA1/2突变与总体严重血液学毒性风险升高无关,但紫杉类治疗下胚系BRCA1/2突变组血液学毒性GIII-IV发生率更高(59.5%对43.1%,p<0.001)。

要点

  • 第一周期中性粒细胞减少GIII-IV发生率在胚系BRCA1/2突变组与野生型组间无显著差异(37.4%对35.7%,P=0.683)。
  • 多因素回归显示胚系BRCA1/2突变不预测第一周期中性粒细胞减少GIII-IV(OR 1.26,95%CI 0.87-1.82)或其他血液学毒性GIII-IV(OR 0.91,95%CI 0.64-1.31)。
  • 紫杉类治疗下胚系BRCA1/2突变组血液学毒性GIII-IV发生率高于野生型(59.5%对43.1%,p<0.001)。

核心结论

  • 在TNBC标准新辅助化疗下,胚系BRCA1/2突变与第一周期或全部周期累计的总体严重血液学毒性风险升高无关。
  • 紫杉类治疗时胚系BRCA1/2突变患者可能有更高的血液学毒性GIII-IV风险,需进一步研究。

研究设计与样本

  • 分析德国乳腺组(GBG)与妇科肿瘤工作组乳腺组(AGO-B)研究中早期三阴性乳腺癌(TNBC)患者,已知胚系BRCA1/2突变状态并接受蒽环-紫杉类新辅助化疗。
  • 主要目标为第一周期(C1)中性粒细胞减少GIII-IV发生率,次要目标包括第一周期其他血液学毒性GIII-IV、全部周期累计血液学毒性、相对总剂量强度及粒细胞集落刺激因子预防。

主要发现

  • 第一周期中性粒细胞减少GIII-IV发生率:胚系BRCA1/2突变组37.4%,野生型组35.7%(P=0.683)。
  • 多因素回归中胚系BRCA1/2突变不预测第一周期中性粒细胞减少GIII-IV(OR 1.26,95%CI 0.87-1.82,P=0.226)或其他血液学毒性GIII-IV(OR 0.91,95%CI 0.64-1.31,P=0.625)。
  • 全部周期累计毒性分析结果类似,但胚系BRCA1突变患者血小板减少GIII-IV增加。
  • 紫杉类治疗患者中,胚系BRCA1/2突变组血液学毒性GIII-IV发生率高于野生型(59.5%对43.1%,p<0.001)。
  • 环磷酰胺或含铂化疗下未见差异。

关键数值与推荐

  • 第一周期中性粒细胞减少GIII-IV:胚系BRCA1/2突变组37.4%,野生型组35.7%(P=0.683)。
  • 第一周期中性粒细胞减少GIII-IV的多因素OR为1.26(95%CI 0.87-1.82,P=0.226),其他血液学毒性GIII-IV的OR为0.91(95%CI 0.64-1.31,P=0.625)。
  • 紫杉类治疗下血液学毒性GIII-IV:胚系BRCA1/2突变组59.5%,野生型组43.1%(p<0.001)。

临床怎么用

  • TNBC新辅助化疗前常规评估胚系BRCA1/2状态时,不应仅因突变状态而普遍加强血液学毒性预防。
  • 紫杉类治疗阶段可对胚系BRCA1/2突变患者加强血象监测,警惕严重血液学毒性。
  • 含铂或环磷酰胺方案下未见突变相关毒性差异,可按常规管理。

局限性

  • 为回顾性分析,来自GBG与AGO-B研究数据。
  • 紫杉类亚组分析结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BRCA1 and BRCA2 play a central role in DNA repair. Therefore, patients harbouring germline (g) BRCA1/2 mutations (m) treated with chemotherapy might be at higher risk of haematological toxicities. METHODS: Patients from German Breast Group (GBG) and Arbeitsgemeinschaft Gynäkologische Onkologie-breast group studies with early triple-negative breast cancer (TNBC) and known gBRCA1/2m status treated with anthracycline-taxane-based neoadjuvant chemotherapy were analysed. Primary objective was the rate of neutropenia grade (G)III-IV in cycle 1 (C1). Secondary objectives included effects on overall and other haematological toxicities GIII-IV in C1, cumulative haematological toxicity across all cycles, relative total dose intensity, and granulocyte-colony stimulating factor prophylaxis. Haematological toxicities under taxanes, carboplatin, and cyclophosphamide were explored. RESULTS: Two hundred nine of 1171 (17.8%) evaluated patients had gBRCA1/2m. In C1, 37.4% gBRCA1/2m versus 35.7% wild-type patients had neutropenia GIII-IV (P = 0.683). For C1, gBRCA1/2m predicted neither for neutropenia GIII-IV (odds ratio [OR]: 1.26, 95% confidence intervals [CI]: 0.87-1.82, P = 0.226) nor for other haematological toxicities GIII-IV (OR: 0.91, 95% CI: 0.64-1.31, P = 0.625) in multivariable regression models. Analyses of cumulative toxicities across all cycles yielded similar results except thrombocytopaenia GIII-IV, which was increased in gBRCA1m patients. In patients treated with taxanes, the rate of haematological toxicities GIII-IV was higher in gBRCA1/2m compared with wild-type (59.5% versus 43.1%; p < 0.001). No difference was seen under cyclophosphamide or platinum-containing chemotherapies. CONCLUSIONS: gBRCA1/2m was not associated with higher risk of overall severe haematological toxicities in the first cycle or cumulatively across all cycles under standard chemotherapy for TNBC. Under taxane, patients with gBRCA1/2m might have a higher risk of haematological toxicities GIII-IV, requiring further research.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Furlanetto J, Möbus V, Schneeweiss A, et al. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2021. PMID: 33423006. doi:10.1016/j.ejca.2020.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。